INTRODUCTION:

The spread of malignant tumours in breast cells is referred to as breast cancer. A control system divides normal cells according to each need¹. When cells lose their capacity to break free, links to other cells, stay under control, and die prematurely, they become malignant. In 85-90 percent of instances, breast cancer is caused by genetic anomalies or mutations, with just 5-10 percent being inherited. It entails the emergence of morally separate, differentiated lesions with distinct biological and molecular characteristics². Breast cancer is a systemic disease that develops when cells that line the milk ducts and mammary glands multiply improperly, travel to different tissues, and then keep growing there. It is a complicated illness that impacts women physically, psychologically, and socially [46]. It is the most frequent cancer in women worldwide and the second leading cause of cancer-related death, behind lung cancer^3,4.

In epidemiological studies, the prevalence was found to be 22–26% and the risk of breast cancer-related mortality was around 18%^5,6. Breast cancer is one of the prevalent cancers in women, impacting one out of every ten of them. The most evident reason of the growth in breast cancer in industrialised nations is ageing; in fact, the probability of breast cancer after age 65 is 5.8 times greater than before age 65, and fifteen times higher than before age 30. A diversification of other risk factors for breast cancer has been found, in addition to growth; nevertheless, all of these varied hazards may be classified into one of two categories: overexposure to estrogens or a lack of genomic integrity maintenance⁷. Breast cancer is the greatest cause of death in Western women, with statistics claiming that roughly a third of all breast cancer after menstruation is linked to oestrogen production, resulting in the development of hormone-dependent cells⁸.

By lowering estrogen levels and preventing cell proliferation, including the creation of genotoxic metabolites of estrogen, artificial intelligence (AI) can prevent breast cancer. Genotoxic estrogen metabolites include (i) catechol estrogens, which bind to DNA covalently and cause mutations that start cancer; (ii) 2-hydroxyl-estradiol, which forms a stable DNA insert; and (iii) 4-hydroxy-estradiol, which may be carcinogenic and causes guanine base 8-hydroxylation, which results in indirect DNA damage caused by estrogen^9-11.

In postmenopausal breast cancer, aromatase inhibitors are the recommended treatment¹². Benzopyranone substrates, like 4-benzyl-3-(4'-chlorophenyl)-7-methoxy-coumarin, have been shown in earlier research to be more competitive than aminoglutethimide. According to reports, this compound's unique interaction with AR results in a higher decrease in binding to the active site of AR and suppresses the growth of AR-positive MCF-7 breast cancer cells that are ER positive^13-15.

There is an over-expressed ER in the breast tumor cell at an early stage of cancer and during hormonal therapy^16-17. Many antitumor agents used in treatment have non-selective effect and acute toxicity so use of these agents in the treatment is limited¹⁸. Conjugation of cytotoxic drug components to a carrier with selective activity to tumor tissues is an effective strategy in the development of effective antitumor drugs with a high therapeutic index^19-24. Studies have shown that combining the cytotoxic agent with steroid hormones provides target selectivity of the conjugate and allow conjugates to accumulate in ER-rich cells as a result of improving antitumor activity and binding to ER^15-27.

Compounds with significant antiproliferative activity on non-invasive and invasive breast cancer cell lines (MDA-MB-231/ATCC and NCI/ADR-RES MDA-MB-435) were found in a study examining the antiproliferative efficacy of novel bioconjugates combining 3-substituted coumarins and estradiol²⁸. These findings may have an impact on the creation of fresh strategies to combat breast cancer²⁹.

According to the American Chemical Society (ACS), more than 250,000 new cases of non-invasive breast cancer were discovered in 2017, with around 40,000 women dying from the disease³⁰. New medicines for the treatment of breast cancer are still being developed, with a high percentage of success³¹. Despite advances in the development of cytotoxic, chemotherapies, endocrine therapies, molecular inhibitors, and breast cancer therapies, metastatic cancer remains a leading cause of death in postmenopausal women, necessitating the development of new therapists and integrated therapies that focus on specific therapies³². The entire therapeutic effectiveness of several heterocyclic compounds is being investigated. The concept of molecular clauses is an essential technique for integrating the therapeutic potential of multiple motifs into a single molecule when looking at novel medication formulations³³. Because of these chemicals' diverse biological actions, they have gained significance in recent times. These compounds have been shown to have antitumor³⁴, photochemotherapy^34-35, anti-HIV³⁶, antibacterial and antifungal³⁷, anti-inflammatory, anticoagulant [inhibitors of the enzyme VKOR (vitamin K epoxide reductase)], triglyceride lowering³⁸, and central nervous system stimulant effects in previous biological activity studies conducted on coumarin derivatives³⁹. Nevertheless, hydroxycoumarins have also been shown to be a potent antioxidant ability to guard against oxidative stress by scavenging reactive oxygen species⁴⁰. The Coumarin nucleus is one of the most potent heterocyclic scaffolds. It is widely known that it has a wide variety of pharmacological actions, with anti-cancer activity being one of the most important⁴¹. Researchers are now focusing their efforts on determining the efficacy of the coumarin nucleus in order to enhance therapeutic agents for breast cancer therapy⁴².

Mechanism of Breast Cancer:

Two groups of predisposing factors have a major role in breast cancer etiology: excessive breast exposure to estrogens and deficiency in maintenance of genomic integrity⁴³.

Fig. (1)

Coumarin Hybrid Concept:

Integrated chemotherapy has emerged as a highly effective approach in the development of novel anti-cancer medicines through molecular hybridization in recent years⁴⁴. It entails the creation of novel ligands based on the discovery of pharmacophores subunits in the structure of two or more existing scaffold cells, as well as the creation of new hybrid compounds that maintain pre-determined real-world motifs' structures⁴⁵. In integrated therapeutics, when multiple chemical treatments are administered with diverse mechanisms of action, the notion of hybrid particles has developed⁴⁶. As a result, molecular mixing entails merging two or more distinct structures into a single molecule in order to assess the therapeutic potential of a single molecule. The hybrid molecule's pharmacophores may or may not operate for the same biological goal⁴⁷. Coumarin is a flexible nucleus that may combine with other strong nuclei at various locations to produce a hybrid molecule⁴⁸. Coumarin characteristics are designed to use the proper locations to join coumarin scaffold with other bioactive motifs in a distinct mode of activity. Coumarin seeds contain anti-cancer properties that are effective against a variety of cancers. This review discusses several types of coumarin hybrid compounds that have been developed for breast cancer⁴⁹.

Thiazole Hybrids of Coumarin:

Isoxazole and thiazole are potent anti-breast cancer medicines found in coumarin hybrid compounds. Chemicals 1-3 have been found to enhance breast cancer activity by two to four times⁵⁰. The most potent compounds 2 and 3 had thiazole moology linked to the coumarin scaffold with a 3rd hydrazinylidene link by the addition of a methyl group in the thiazole ring, according to the construction activity (SAR) relationship Fig. (2). When thiazole is substituted with isoxazole, the activity decreases dramatically. By converting 4-hydroxy coumarin⁵¹, this report aids in the creation of new compounds.

Fig. (2). Coumarin hybrids with Isoxazole/thiazole with best activity.

Coumarin-Monastrol Hybrid:

Unique apoptosis in both lines of primary breast cancer cells (MCF7 and T47D) utilising tamoxifen (TAM) and epirubic medicines in a novel class of chemical coumarin-monastrol hybrid as an anti-astreast cancer agents Chemical characteristics and functions are excellent. When compared to MCF lines 7, the rise in methoxy ring replacement and tertiary butyl substitution in coumarin 10 paraffin exhibited higher potency Fig. (3). In accordance with this, MCF7 demonstrated substantial anti-line activity when pyrimidine was replaced with =S and =O. To further understand the mechanism of action, Casase-3 activation tests and cell cycle analyses in combination 10 were carried out. Apoptosis is triggered when Capase-3 is activated. Due to apoptosis creation, compound 10 enhanced Caspase-3 activities, and cytometric examination indicated cell binding of MCF7 cell lines as a G1 class^52-53.

Fig. (3). Coumarin-Monastrol Hybrid compounds against breast cancer.

Coumarin-pyrazoline Hybrids:

In the synthesis of coumarin-pyrazoline hybrids, a molecular synthesis method was used. The compounds are made up of imidazole fused pyridine and coumarin that have been bio-isosterically substituted. MCF7, BT549, T-47D, and MDA-MB468 cell lines were used to assess the compounds' breast cancer activities. In all cell lines, the compounds were shown to be quite potent. According to SAR study, adding an electron-releasing atom to the 4th position of the phenyl sulfonyl moiety produces compounds with strong anti-cancer properties while having no effect on the aryl position in the 5th position of the pyrazoline ring Fig. (4). they chose to test the activity of the phosphoinositide 3-kinase inhibitory to explore the mechanism of action of the combination compounds. The development of signalling pathways important in cell proliferation, growth, metabolism, and metabolism is linked to PI3K^54-56.

Fig. (4). Most potent Coumarin-Pyrazoline hybrid compounds.

Coumarin-Chalcone Hybrids:

Instead of a chalcone B ring, a succession of coumarin chalcone characters with various components. SRB-based spectrophotometry was used to assess their anti-proliferation effects against three distinct breast cancer lines (MDAMB231, MDA-MB468 and MCF7), as well as one non-cancerous epithelial cell line (184B5). The reference medication cisplatin is compared to the extremely powerful chemical 14-16. SAR tests revealed that putting two chloro groups in alternating regions of the phenyl ring resulted in modest activity, but putting three methoxy groups in the first three places of the phenyl ring resulted in a substantial increase in activity across all cell lines Fig. (5). Most potent Coumarin-Chalcone Hybrid compounds. Thus, the reported chemical activity is clearly dependent on the replacement pattern and locations of the absorbed compounds and the reported chemicals can be utilised as novel drug development guidelines^57-58.

Fig. (5). Most potent Coumarin-Chalcone Hybrid compounds

Coumarin-triazole Hybrids:

For the creation of novel bioactive chemicals, the triazole ring is a key heterocyclic. This electron's heterocyclic richness makes it easy to attach to a variety of enzymes and receptors. Using BT20 cell lines and cisplatin as a reference medication, a combination of coumarin triazole hybrids was evaluated for anti-tumor efficacy against breast cancer Fig. (6). Bromobenzyl replacement in the triazole ring and diethylamide replacement in the coumarin nucleus were anticipated to generate highly effective molecules in SAR analyses, but dichloro-containing hybrids exhibited intermediate activity⁵⁹.

Fig. (6). Coumarin-triazole Hybrid compounds

Coumarin-Sulphonamide Hybrids

The combination of coumarin 3 (N-aryl) sulphonamides was also evaluated for anticancer efficacy, with BT-20 cell lines showing a 50% reduction of breast cancer development. The presence of the electron Br emitting group in the 4th position of the phenyl ring and the eighth position of coumarin 23 exhibited outstanding performance in SAR tests, and the modification in the 8th position lowered this activity significantly⁶². Depending on the type and placements of the actors, the visual activity pattern changed. The Immune Kinase Assay was used to examine the production of JNK1 in order to learn more about how synthetic compounds work Fig. (7). JNKs are kinases that have been linked to cell growth and death inhibition. Synthetic compounds have been found to activate JNK1, implying that these substances might be used as novel naming mechanisms for new breast cancer candidates⁶¹.

Fig. (7). Coumarin-sulphonamide derivatives with maximum potency.

Coumarin-Benzothiazole Hybrids

Because of its broad biological profile, benzothiazole is a well-known molecule in medicinal chemistry⁶². So a series of coumarin-benzothiazole anti-breast cancer vaccines were developed to investigate the therapeutic potential of benzothiazole and coumarin motifs in a single therapist. In MCF7 cell lines, combined compounds were evaluated for anti-breast cancer efficacy by measuring percentage growth inhibition and IC50 values Fig. (8). Chemicals 78 and 79 grew at a rate of 78.68 and 79.40 percent, respectively, with IC50 values of 50.00 and 59.80 M / ml. The addition of the acetoxy group in the third location of the coumarin phenyl ring and methyl sulphide in the second place created highly active molecules, according to the findings^63-65.

Fig. (8). Most potent Coumarin-Benzothiazole Hybrids.

Coumarin-Pyrimidine Hybrids:

The methylene thio link is used to create a series of coumarin pyrimidine hybrid compounds. Using 5fluoro uracil as a reference, combined compounds were tested against MCF7 cell lines to see if they worked against breast cancer. Chemicals having MIC values of 6.9 0.38g/mL and 10.9 0.97g/mL, respectively, showed significant cytotoxic action. SAR may be characterised as inserting a pyrimidine motif with hydrazine or piperazine to produce a significant level of activity, according to bought data⁶⁶. However, substituting these groups with aniline or morpholine results in a substantial drop in performance, demonstrating that the molecule must carry hydrogen bond suppliers as a group in order to receive a sufficient quantity of energy. In the positioning of docs against kinase-2-dependent cyclin, the most powerful component was examined. CDKs play a crucial role in cell proliferation and division, which makes them good candidates for therapeutic development against different malignancies Fig. (9).. The target molecule enters the hole and stays in the same active site pocket, forming a hydrogen and amino acid connection, according to docking studies. According to these investigations, CDK2 activity inhibited the hypothesised action against the proliferation of these substances^67-68.

Fig. (9). Most potent Coumarin-Pyrimidine hybrids

Coumarin-Imidazo [1, 2-a] Pyrazine Hybrids:

Combining two heterocyclic biologically active particles [1, 2-a] pyrazine and coumarin to create a hybrid compound. The suppression of percentage growth in MCF7, MDA-MB231, HS5787, BT549, T47D, and MDA-MB468 cell lines was further evaluated for combined chemical action using 6-fluoro uracil (5-FU) as a reference medication. In diverse cell lines, the computer has introduced a wide spectrum of growth inhibitors. The installation of two thiophen rings in levels 3 and 6 raised activity somewhat, whereas the installation of phenyl rings and 4-methoxy phenyl rings in the same regions enhanced activity at greater costs, according to the construction work connection. Bromo's simple installation has shown to be a decent percentage barrier in these situations Fig. (10). the kinase protein involved in transmitting signals within cells to control cell development was studied using molecular docking of compounds. The combination revealed N7 atom interacting with M517 amino acid residues in grade 2.17Å, as well as N1 and N4 atoms establishing hydrogen bonds with G518 amino acid residues in grades 2.72 and 1.75Å, respectively. Away from 2.85Å, the oxygen atom of the 4-methoxy group formed H-bond interactions with R781 amino acid residues. At a range of 2.31 Å, the Carbonyl coumarin group establishes H-bonding interactions with Q530 amino acid residues. The suggested mechanism of action of synthetic drugs is suppression of B-Raff kinase activity, based on the binding pattern of integration and its function⁶⁹.

Fig. (10). Most potent Coumarin-Imidazo [1,2-a] Pyrazine Hybrids.

Nano formulation of coumarin derivatives for breast cancer:

Nanostructures and other guest molecules are basis of nano formulation studies. The basis of Nano formulation studies is divided into two main categories; guest molecules and nanocarrier. The nanocarrier with some nanostructures such as multifunctional nanocapsules, have the character of containers that can be loaded with various cargoes and then become promising nanocarrier for diagnostic and drug delivery, or some biomedical applications. Such Nanoparticles (NPs) or nanocarrier can be charged with many guest molecules, such as hydrophobic therapeutics, optically active organic molecules, metal complexes, ultrasonic contrast agents, metal oxides, etc. and the particles may also change the potential solubility problems and biocompatibility of the guest molecules. The present positions of the manufactured nanoparticles allow for combining different properties for the drug delivery and diagnostic systems. Thus, the guest molecules can be transported to the desired sites and however, some modifications to the particles may be required such as shape, stability, physical state, charge, permeability, environmental responsiveness etc. In addition to the combination of all these properties, the nanocarrier and the guest molecules must be in harmony and serve the same target⁷⁰. The coumarins are also used in many research guest molecules and the use of coumarins in nanomaterial’s is also increasing. In the drug delivery system, there are mainly carrier particles, guest molecules and support molecules for detecting/imaging the system. In addition to being guest molecules, the coumarin and their derivative compounds can also serve to visualize the formulations. In this sense, the Coumarin-6 is one of the most commonly used compounds in formulation studies⁷¹. This compound is one of both benzene-substituted and pyrano-substituted coumarin derivatives and has been used as a fluorescence molecule for marking NPs in many formulation studies

CONCLUSION:

A medicinal chemist's primary consideration is to focus on a single target (receptor, enzyme, or protein) to develop a novel therapy, but it is also true that a single target strategy does not result in complicated and complex illnesses with a single malignancy among them. For decades, scientists have been drawn to the ring system by its vast dispersion and abundance of coumarin compounds. These chemicals have shown a number of key processes in the synthesis of coumarin and other breast cancer-treatment molecules. These newly discovered breeds have the potential to become a new leader in improving drug research with more vigour and variety. This brief review will aid the researcher in developing new methods of working and the structure of the constructing connection in order to create more strong chemical novels. Aside from the numerous benefits of molecular mixing, there are also typical drawbacks, such as high lipophilicity and instability owing to complicated chemical characteristics. As a result, while designing novel coumarins, researchers should use the proper design technique to try to overcome these constraints.

REFERENCES:

1. Hsiao YH, Chou MC, Fowler C, Mason JT, Man YG. Breast cancer heterogeneity: mechanisms, proofs, and implications. Journal of Cancer. 2010; 1: 6.

2. Becker S. A historic and scientific review of breast cancer: The next global healthcare challenge. International Journal of Gynaecology & Obstetrics. 2015 Oct; 131: S36-9.

3. Bhatia R, Rawal RK. Coumarin Hybrids: Promising Scaffolds in the Treatment of Breast Cancer. Mini Reviews in Medicinal Chemistry. 2019 Oct 1; 19(17):1443-58.

4. Hussein O, Kemerovo SV. Breast cancer at bone metastatic sites: recent discoveries and treatment targets. Journal of Cell Communication and Signalling. 2011 Jun 1; 5(2):85-99.

5. Ravnan MC, Ravnan SL, Walberg MP. Metastatic breast cancer: A review of current and novel pharmacotherapy. Formulary. 2011 Apr 1; 46(4).

6. BaLLazhI L, PoPovSki E, JAShAri A, Imeri F, and Ibrahimi I, Mikhova B, Mladenovska K. Potential antiproliferative effect of isoxazolo-and thiazolo coumarin derivatives on breast cancer mediated bone and lung metastases. Acta Pharmaceutical. 2015 Mar 1; 65(1):53-63.

7. Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, and Winer EP, Cardoso F. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? Journal of the National Cancer Institute. 2010 Jan 1; 102(7):456-63.

8. Sashidhara KV, Kumar M, Sonkar R, Singh BS, Khanna AK, Bhatia G. Indole-based fibrates as potential hypolipidemic and antiobesity agents. Journal of Medicinal Chemistry. 2012 Mar 22; 55(6): 2769-79.

9. Chen S, Cho M, Karlsberg K, Zhou D, Yuan YC. Biochemical and biological characterization of a novel anti-aromatase coumarin derivative. Journal of Biological Chemistry. 2004 Nov 12; 279(46): 48071-8.

10. Musa MA, Cooper wood JS, Khan MO. A review of coumarin derivatives in pharmacotherapy of breast cancer. Current medicinal chemistry. 2008 Nov 1; 15(26): 2664-79.

11. Bhatia R, Rawal RK. Coumarin Hybrids: Promising Scaffolds in the Treatment of Breast Cancer. Mini Reviews in Medicinal Chemistry. 2019 Oct 1; 19(17):1443-58.

12. Lewis JS, Jordan VC. Selective estrogens receptor modulators (SERMs): mechanisms of ant carcinogenesis and drug resistance. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2005 Dec 11; 591(1-2):247-63.

13. Harada K, Kubo H, Tomigahara Y, Nishioka K, Takahashi J, Momose M, Inoue S, Kojima A. Coumarins as novel 17β-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer. Bioorganic & Medicinal Chemistry Letters. 2010 Jan 1; 20(1):272-5.

14. BaLLazhI L, PoPovSki E, JAShAri A, Imeri F, and Ibrahimi I, Mikhova B, Mladenovska K. Potential antiproliferative effect of isoxazolo-and thiazolo coumarin derivatives on breast cancer mediated bone and lung metastases. Acta Pharmaceutical. 2015 Mar 1; 65(1):53-63.

15. Sashidhara KV, Avula SR, Sharma K, Palnati GR, Bathula SR. Discovery of coumarin–monastrol hybrid as potential antibreast tumor-specific agent. European Journal of Medicinal Chemistry. 2013 Feb 1; 60:120-7.

16. You L, An R, Wang X, Li Y. Discovery of novel osthole derivatives as potential anti-breast cancer treatment. Bioorganic & Medicinal Chemistry Letters. 2010 Dec 15; 20(24):7426-8.

17. Patel K, Karthikeyan C, Raja Solomon V, S Hari Narayana Moorthy N, Lee H, Sahu K, Singh Deora G, Trivedi P. Synthesis of some coumarinyl chalcones and their antiproliferative activity against breast cancer cell lines. Letters in Drug Design & Discovery. 2011 May 1; 8(4):308-11.

18. Kahveci B, Yılmaz F, Menteşe E, Ülker S. Design, synthesis, and biological evaluation of coumarin–triazole hybrid molecules as potential antitumor and pancreatic lipase agents. Archive Der Pharmazie. 2017 Aug; 350(8):1600369.

19. Reddy NS, Mallireddigari MR, Cosenza S, Gumireddy K, Bell SC, Reddy EP, Reddy MR. Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity. Bioorganic & Medicinal Chemistry Letters. 2004 Aug 2; 14(15):4093-7.

20. Kini SG, Choudhary S, Mubeen M. Synthesis, docking study and anticancer activity of coumarin substituted derivatives of benzothiazole. Journal of Computational Methods in Molecular Design. 2012 Dec; 2(1):6.

21. Sashidhara KV, Kumar A, Kumar M, Sarkar J, Sinha S. Synthesis and in vitro evaluation of novel coumarin–chalcone hybrids as potential anticancer agents. Bioorganic & Medicinal Chemistry Letters. 2010 Dec 15; 20(24):7205-11.

22. Morsy SA, Farahat AA, Nasr MN, Tantawy AS. Synthesis, molecular modeling and anticancer activity of new coumarin containing compounds. Saudi Pharmaceutical Journal. 2017 Sep 1; 25(6):873-83.

23. Goel R, Luxami V, Paul K. Synthesis, in vitro anticancer activity and SAR studies of arylated imidazo [1, 2-a] pyrazine–coumarin hybrids. RSC Advances. 2015; 5(47):37887-95.

24. Sharif, N.M.; Mustahil, N.; Noor, N.M.; Sukari, M.; Rahmani, M.; Taufiq-Yap, Y.; Ee, G. Cytotoxic constituents of Clausena excavata. Afr. J. Biotechnol., 2011, 10(72), 16337-16341. [113] Yao, G-D.; Cheng, Z-Y.; Shang, X-Y.; Gao, P-Y.; Huang, X-X.; Song, S-J. Coumarins from the bark of Juglans mandshurica exhibited anti-hepatoma activities via inducing apoptosis. J. Asian Nat. Prod. Res., 2017, 19(11), 1134-1142.

25. Chun, J.; Kim, J.; Kim, Y.S. 3′, 4′-Disenecioylkhellactone from Peucedanum japonicum Thunb. Induces apoptosis mediated by inhibiting STAT3 signaling in human gastric cancer cells. Korean J. Pharmacogn., 2018, 49(3), 225-230.

26. Maleki, D.; Kyoomehr, P.; Rajabi, A.; Amin, G.; Azizi, E. Cytotoxic activity of Ammi visnaga (L.) Lam. against T47D (breast ductal carcinoma) cell line. North Khorasan Univ. Med. Sci., 2012.

27. Shen, X.; Chen, G.; Zhu, G.; Cai, J.; Wang, L.; Hu, Y.; Fong, W.F. 3′-O, 4′-O-aromatic acyl substituted 7,8-pyranocoumarins: a new class of P-glycoprotein modulators. J. Pharm. Pharmacol., 2012, 64(1), 90-100.

28. Kathuria, A.; Jalal, S.; Tiwari, R.; Shirazi, A.N.; Gupta, S.; Kumar, S.; Parang, K.; Sharma, S.K. Substituted coumarin derivatives: Synthesis and evaluation of antiproliferative and Src kinase inhibitory activities. Chem. Biol. Interface, 2011, 1, 279-296.

29. Ren, L.; Du, X.; Hu, M.; Yan, C.; Liang, T.; Li, Q. Design, synthesis and antitumor activity of novel 4-methyl-(3‘S,4’S)-ciskhellactone derivatives. Molecules, 2013, 18(4), 4158-4169.

30. Jóźwiak, M.; Struga, M.; Roszkowski, P.; Filipek, A.; Nowicka, G.; Olejarz, W. Anticancer effects of alloxanthoxyletin and fatty acids esters - In vitro study on cancer HTB-140 and A549 cells. Biomed. Pharmacotherapy. 2019, 110, 618-630.

31. Ostrowska, K.; Olejarz, W.; Wrzosek, M.; Głuszko, A.; Nowicka, G.; Szczepański, M.; Materek, I.B.; Kozioł, A.E.; Struga, M. Anticancer effects of O-aminoalkyl derivatives of alloxanthoxyletin and seselin. Biomed. Pharmacother., 2017, 95, 1412-1424.

32. Shi, W.; Zhang, J.; Bao, N.; Guan, F.; Chen, L.; Sun, J. Design, synthesis, and cytotoxic evaluation of novel scopoletin derivatives. Chem. Biol. Drug Des., 2018, 91(2), 641-646.

33. Küpeli Akkol, E., Genç, Y., Karpuz, B., Sobarzo-Sánchez, E. and Capasso, R. Coumarins and coumarin-related compounds in pharmacotherapy of cancer. Cancers. 2020; 12(7): 1959.

34. Vianna, D.R.; Hamerski, L.; Figueiró, F.; Bernardi, A.; Visentin, L.C.; Pires, E.N.; Teixeira, H.F.; Salbego, C.G.; Eifler-Lima, V.L.; Battastini, A.M.; et al. Selective cytotoxicity and apoptosis induction in glioma cell lines by 5-oxygenated-6,7-methylenedioxycoumarins from Pterocaulon species. Eur. J. Med. Chem. 2012, 57, 268–274.

35. Harvey, R.G.; Cortex, C.; Ananthanarayan, T.P.; Schmolka, S. A new coumarin synthesis and its utilization for the synthesis of polycyclic coumarin compounds with anticarcinogenic properties. J.Org. Chem. 1988, 53, 3936–3943.

36. Kostova, I.; Momekov, G.; Tzanova, T.; Karaivanova, M. Synthesis, characterization, and cytotoxic activity of new lanthanum (III) complexes of bis-coumarins. Bioinorg. Chem.Appl. 2006, 25651, 1–9.

37. Al-Haiza, M.A.; Mostafa, M.S.; El-Kady, M.Y. Synthesis and Biological Evaluation of Some New Coumarin Derivatives. Molecules 2003, 8, 275–286.

38. Musiciki, B.; Periers, A.M.; Laurin, P.; Ferroud, D.; Benedetti, Y.; Lachaud, S.; Chatreaux, F.; Haesslein, J.L.; Lltis, A.; Pierre, C.; et al. Improved antibacterial activities of coumarin antibiotics bearing 5’,5’-dialkylnoviose: Biological activity of RU79115. Bioorg. Med. Chem. Lett. 2000, 10, 1695–1699.

39. Tosun, A.; Kupelı, E.; Yesılada, E. Anti-Inflammatory and Antinociceptive Activity of Coumarins from Seseli gummiferum subsp. corymbosum (Apiaceae). Z. Nat. C. 2009, 64c, 56–62.

40. Fylaktakidou, K.C.; Hadipavlou-Litina, D.J.; Litinas, K.E.; Nicolaides, D.N. Natural and synthetic coumarin derivatives with anti-inflammatory/ antioxidant activities. Curr. Pharm. Des. 2004, 10, 3813–3833.

41. Jung, J.; Kin, J.; Park, O.S. A convenient one-pot synthesis of 4-hydroxycoumarin, 4-hydroxythiocoumarin, and 4-hydroxyquinolin-2(1H)-one. Synth. Commun. 2001, 31, 1195–1200.

42. Hoult, J.R.; Payá, M. Pharmacological and biochemical actions of simple coumarins: Natural products with therapeutic potential. Gen. Pharmacol. 1996; 27: 713–722.

43. Madhavan, G.R.; Balraju, V.; Malleshasm, B.; Chakrabarti, R.; Lohray, V.B. Novel coumarin derivatives of heterocyclic compounds as lipid-lowering agents. Bioorg. Med. Chem. Lett. 2003; 13: 2547–2551.

44. Moffet, R.S. Central Nervous System Depressants. VII. Pyridyl Coumarins. J. Med. Chem. 1964; 7: 446–449.

45. Paya, M.; Halliwell, B.; Hoult, J.R. Interactions of a series of coumarins with reactive oxygen species. Scavenging of superoxide, hypochlorous acid and hydroxyl radicals. Biochem. Pharmacol. 1992; 44: 205–214.

46. Stacey, D.; DeGrasse, C.; Johnston, L. Addressing the support needs of women at high risk for breast cancer: Evidence-based care by advanced practice nurses. Oncol. Nurs. Forum. 2002; 29: 77–84.

47. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 2015; 65: 5–29.

48. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011; 61: 69–90.

49. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer. 2001; 94: 153–156.

50. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 2001, 94, 153–156.

51. Roy, D.; Liehr, J.G. Estrogen, DNA damage and mutations. Mutat. Res. 1999; 424: 107–115.

52. Liehr, J.G. Genotoxicity of the steroidal oestrogens oestrone and oestradiol: Possible mechanism of uterine and mammary cancer development. Hum. Reprod. Update. 2001; 7: 273–281.

53. Russo, J.; Russo, I.H. Genotoxicity of steroidal estrogens. Trends Endocrinol. Metab. 2004; 15: 211–214.

54. Cuzick, J.; Sestak, I.; Forbes, J.F.; Dowsett, M.; Knox, J.; Cawthorn, S.; Saunders, C.; Roche, N.; Mansel, R.E.; von Minckwitz, G.; et al. IBIS-II investigators, Anastrozole for prevention of breast cancer in highrisk postmenopausal women (IBIS-II): An international, double-blind, randomised placebocontrolled trial. Lancet. 2014; 383: 1041–1048.

55. Leonetti, F.; Favia, A.; Rao, A.; Aliano, R.; Paluszcak, A.; Hartmann, R.W.; Carotti, A. Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors. J. Med. Chem. 2004; 47: 6792–6803.

56. Recanatini, M.; Cavalli, A. Comparative molecular field analysis of non-steroidal aromatase inhibitors: An extended model for two different structural classes. Bioorg. Med. Chem. 1998; 6; 377–388.

57. Gotteland, M.; May, E.; May-Levin, F.; Contesso, G.; Delarue, J.C.; Mouriesse, H. Estrogen receptors (ER) in human breast cancer. The significance of a new prognostic factor based on both ER protein and ER mRNA contents. Cancer. 1994; 74: 864–871.

58. Soubeyran, I.; Quenel, N.; Mauriac, L.; Durand, M.; Bonichon, F.; Coindre, J.M. Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: A study of 74 cases. Br. J. Cancer. 1996; 73: 735–743.

59. Devraj, R.; Barrett, J.F.; Fernandez, J.A.; Katzenellenbogen, J.A.; Cushman, M. Design, synthesis, and biological evaluation of ellipticine-estradiol conjugates. J. Med. Chem. 1996; 39: 3367–3374.

60. Krohn, K.; Kulikowski, K.; Leclercq, G. Diethylstilbestrol-linked cytotoxic agents: Synthesis and binding affinity for estrogen receptors. J. Med. Chem. 1989; 32: 1532–1538.

61. Schmidt, B.F.; Hernandez, L.; Rouzer, C.; Czerwinski, G.; Chmurny, G.; Michejda, C.J. Peptide-linked 1,3-dialkyl-3-acyltriazenes: Gastrin receptor directed antineoplastic alkylating agents. J. Med. Chem. 1994; 37: 3812–3818.

62. Varga, J.M.; Asato, N.; Lande, S.; Lerner, A.B. Melanotropin-daunomycin conjugate shows receptor-mediated cytotoxicity in cultured murine melanoma cells. Nature. 1977; 267: 56–58.

63. Nakagawa-Goto, K.; Yamada, K.; Nakamura, S.; Chen, T.H.; Chiang, P.C.; Bastow, K.F.; Wang, S.C.; Spohn, B.; Hung, M.C.; Lee, F.Y.; et al. Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant–taxoid conjugates as novel cytotoxic agents. Bioorg. Med. Chem. Lett. 2007; 17: 5204–5209.

64. Ahmed, N.; Dubuc, C.; Rousseau, J.; Benard, F.; van Lier, J.E. Synthesis, characterization, and estrogen receptor binding affinity of flavone-, indole-, and furan-estradiol conjugates. Bioorg. Med. Chem. Lett. 2007, 17, 3212–3216.

65. Ali, H.; Ahmed, N.; Tessier, G.; van Lier, J.E. Synthesis and biological activities of nucleoside-estradiol conjugates. Bioorg. Med. Chem. Lett. 2006; 16: 317–319.

66. James, D.A.; Swamy, N.; Paz, N.; Hanson, R.N.; Ray, R. Synthesis and estrogen receptor binding affinity of a porphyrin-estradiol conjugate for targeted photodynamic therapy of cancer. Bioorg. Med. Chem. Lett. 1999; 9: 2379–2384.

67. Swamy, N.; James, D.A.; Mohr, S.C.; Hanson, R.N.; Ray, R. An estradiol-porphyrin conjugate selectively localizes into estrogen receptor-positive breast cancer cells. Bioorg. Med. Chem. 2002; 10: 3237–3243.

68. Liu, C.; Strobl, J.S.; Bane, S.; Schilling, J.K.; McCracken, M.; Chatterjee, S.K.; Rahim-Bata, R.; Kingston, D.G. Design, synthesis, and bioactivities of steroid-linked taxol analogues as potential targeted drugs for prostate and breast cancer. J. Nat. Prod. 2004: 67: 152–159.

69. Musa, M.A.; Cooperwood, J.S.; Khan, M.O.F. A Review of Coumarin Derivatives in Pharmacotherapy of Breast Cancer. Curr. Med. Chem. 2008; 15: 2664–2679.

70. Chen, S.; Cho, M.; Karlsberg, K.; Zhou, D.; Yuan, Y.C. Biochemical and biological characterization of a novel anti-aromatase coumarin derivative. J. Biol. Chem. 2004; 279: 48071–48078.

71. Cui, N.; Lin, D.-D.; Shen, Y.; Shi, J.-G.; Wang, B.; Zhao, M.-Z.; Zheng, L.; Chen, H.; Shi, J.-H. Triphenylethylene-Coumarin Hybrid TCH-5c Suppresses Tumorigenic Progression in Breast Cancer Mainly Through the Inhibition of Angiogenesis. Anti. Cancer Agents Med. Chem. 2019; 19: 1253–1261.

Received on 08.04.2024 Modified on 16.07.2024

Research J. Pharm. and Tech 2024; 17(10):4934-4940.

DOI: 10.52711/0974-360X.2024.00759